Abstract
Study design:
An observational study based on retrospective review of the medical charts and death records of 163 individuals with traumatic spinal cord injuries (SCI).
Objectives:
To determine whether HMG coA Reductase Inhibitor (‘statin’) use in a cohort of patients with traumatic SCI reduced overall and cause-specific mortality.
Setting:
An outpatient clinic designated for veterans with SCI at the Oklahoma City Veterans Administration Hospital.
Methods:
Review and analysis of the medical records of 163 veterans with traumatic SCI cared for between the years 2000 and 2014. Data collected included statin use, duration of statin use and intensity of statin therapy, as well as cause-specific mortality.
Results:
Seventy five participants had taken statins for an average of 5.7±3.7 years, and had greater cardiovascular risk burdens than those who had not taken statins (n=88). Statin use was associated with a reduced risk of death. The mortality rate for those patients on statins was 33.8–49.9 per 1000 person-years, depending on assumptions made regarding residual effects of statin use. Under most assumptions this was significantly lower than the mortality rate seen in those not on statins (47.4–66.8 deaths per 1000 person-years). Within the statin group, neither duration nor average intensity of statin therapy affected mortality.
Conclusion:
Statin use among a cohort of veterans with traumatic SCI reduced all-cause mortality. This retrospective study ought to spur further investigations into the potential benefits of statin use among people with chronic SCI, and begin a discussion as to whether individuals with injuries should routinely be offered statin therapy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bauman W, Raza M, Spungen A, Machac J . Cardiac stress testing with Thallium-201 imaging reveals silent ischemia in individuals with paraplegia. Arch Phys Med Rehabil 1994; 75: 946–950.
Lee CS, Lu YH, Lee ST, Lin CC, Ding HJ . Evaluating the prevalence of silent coronary artery disease in asymptomatic patients with spinal cord injury. Int Heart J 2006; 47: 325–330.
Orakzai SH, Orakzai RH, Ahmadi N, Agrawal N, Bauman WA, Yee F et al. Measurement of coronary artery calcification by electron beam computerized tomography in persons with chronic spinal cord injury: evidence for increased atherosclerotic burden. Spinal Cord 2007; 45: 775–779.
Bell J, Chen D, Bahls M, Newcomer S . Evidence for greater burden of peripheral arterial disease in lower extremity arteries of spinal cord-injured individuals. Am J Physiol Heart Circ Physiol 2011; 301: H766–H772.
Groah S, Charlifue S, Tate D, Jensen M, Molton I, Forchheimer F et al. Spinal cord injury and aging: challenges and recommendations for future research. Am J Phys Med Rehabil 2012; 91: 80–93.
National Spinal Cord Injury Statistical Center (NSCISC)https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202013.pdf. Accessed on 3 October 2014.
Devivo M, Krause S, Lammertse D . Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 1999; 80: 1411–1419.
Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, Gagnon D et al. A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord 2005; 43: 408–416.
Nash M, Lewis J, Dyson-Hudson T, Szlachcic Y, Yee F, Mendez A et al. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: A randomized multicenter controlled trial. Arch Phys Med Rehabil 2011; 92: 399–410.
Saunders LL, Clarke A, Tate DG, Forchheimer M, Krause JS . Lifetime prevalence of chronic health conditions among persons with spinal cord injury. Arch Phys Med Rehabil 2015; 96: 673–679.
Flank P, Wahman K, Levi R, Fahlström M . Prevalence of risk factors for cardiovascular disease stratified by body mass index categories in patients with wheelchair-dependent paraplegia after spinal cord injury. J Rehabil Med 2012; 44: 440–443.
Rabadi MH, Mayanna SK, Vincent AS . Predictors of mortality in veterans with traumatic spinal cord injury. Spinal Cord 2013; 51: 784–788.
Stone N, Robinson J, Lichtenstein A, Bairy Merz C, Blum C, Eckel R et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2013; 129: S1–45.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). The Lancet 1994; 344: 1383–1389.
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Gole T et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
Collins R, Armitage J, Parish S, Sleigh P, Peto R . MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet 2003; 361: 2005–2016.
Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39: 1871–1878.
Nielsen A, Nielsen R, Riis A, Johnsen S, Sorensen H, Thomsen R . The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care 2012; 16: R122.
Douglas I, Evans S, Smeeth L . Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011; 342: d1642.
Schlienger R, Fedson D, Jick S, Jick H, Meier C . Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27: 325–332.
Chalmers J, Short P, Mandal P, Akram A, Hill A . Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med 2010; 104: 1081–1091.
Troeman DPR, Postma DF, van Werkhoven CH, Oosterheert JJ . Immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect 2013; 67: 93–101.
Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2014; 350: 1495–1504.
LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
Liao J, Laufs U . Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118.
Davignon J . Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39–III43.
Acknowledgements
CEA was funded for this study by the National Institutes of Health, National Institute of General Medical Sciences, grant 1 U54GM104938.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Stillman, M., Aston, C. & Rabadi, M. Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. Spinal Cord 54, 298–302 (2016). https://doi.org/10.1038/sc.2015.180
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2015.180
This article is cited by
-
Statin use is associated with reduced motor recovery after spinal cord injury
Spinal Cord Series and Cases (2021)
-
Guideline for the identification and management of cardiometabolic risk after spinal cord injury: a case of unsubstantiated recommendations
Spinal Cord Series and Cases (2019)
